Biologic rebate contracts for insulin-isophan and insulin
Original notice title
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-13 - Insulin-isophan/Insulin, normal (human) (Wirkstoffkombination)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No volume guarantee or exclusivity; revenue depends on market uptake and number of competitors.
The notice explicitly states this is not a public procurement; any legal challenges must go through social courts, not...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 30, 2027
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Jul 2027
- Conclusion of discount agreements (Rabattverträge) for the supply of insulin isophane/insulin normal (human) combination products in two forms: cylinder ampoules and pre-filled pens.
- Supply to the German healthcare market (nationwide).
Show full summary
This is an Open House procedure by Techniker Krankenkasse (TK) for concluding discount agreements on insulin isophane/insulin normal (human) combination products in two dosage forms: cylinder ampoules (Lot 1) and pre-filled pens (Lot 2). The contract period runs from 01.08.2025 to 31.07.2027 (max 24 months). No estimated value is provided. The procedure is open to all eligible pharmaceutical manufacturers meeting strict criteria (pharmaceutical entrepreneur with valid marketing authorization, EU/EEA establishment). Contracts are concluded on uniform terms without negotiation; no exclusivity is granted. The notice clarifies this is not a public procurement subject to procurement law. No procurement documents were analyzed beyond the notice.
Risks
No volume guarantee or exclusivity; revenue depends on market uptake and number of competitors.
The notice explicitly states this is not a public procurement; any legal challenges must go through social courts, not...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per § 4 Abs. 18 AMG with respect to the offered medicinal product.
- Must have a valid marketing authorization within the AMG scope or equivalent.
- Must have registered office within Germany, EU, or EEA.
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (2)
LOT-0001
Insulin-isophan/Insulin, normal (human) (Wirkstoffkombination) (Darreichungsform: Zylinderampullen)
Discount agreement for insulin isophane/insulin normal (human) combination in cylinder ampoules. Contract period 01.08.2025-31.07.2027.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zur Wirkstoffkombination Insulin-isophan/Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Value note
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zur Wirkstoffkombination Insulin-isophan/Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
LOT-0002
Insulin-isophan/Insulin, normal (human) (Wirkstoffkombination) (Darreichungsform: Fertigpen)
Discount agreement for insulin isophane/insulin normal (human) combination in pre-filled pens. Contract period 01.08.2025-31.07.2027.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zur Wirkstoffkombination Insulin-isophan/Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Value note
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zur Wirkstoffkombination Insulin-isophan/Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Procurement Details
- Publication date
- 11 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 300967-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No volume guarantee or exclusivity; revenue depends on market uptake and number of competitors.
The notice explicitly states this is not a public procurement; any legal challenges must go through social courts, not...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications